BOSTON, July 09, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq:ZIOP), today announced the initiation of a phase 1 clinical trial to evaluate CD19-specific CAR-T, using its Rapid Personalized Manufacturing (RPM) technology, as an investigational treatment for patients with relapsed CD19+ leukemias and lymphomas. The trial is now open for enrollment at The University of Texas MD Anderson Cancer Center.

In this trial, the Company utilizes its non-viral Sleeping Beauty genetic engineering technology to infuse CAR-T the day after electroporation. Ziopharms RPM CD19-specific CAR-T therapy results from the stable, non-viral insertion of DNA into the genome of resting T cells to co-express the chimeric antigen receptor (CAR), membrane-bound IL-15 (mbIL15) and a safety switch.

We are pleased to expand the scope of our clinical development with MD Anderson, as we seek to evaluate our RPM technology using CD19-specific CAR-T cells, said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm. RPM is a promising manufacturing solution, as T cells from the bloodstream are genetically reprogramed with DNA plasmids from the Sleeping Beauty system and then simply administered the next day.

Our CAR-T therapy can be administered at low cell doses, which may control cytokine release syndrome and is appealing for the treatment of patients including those with CD19-expressing malignancies that have relapsed after allogeneic bone marrow transplantation (BMT). There are limited effective treatment options for such patients as evidenced by the low rate of remission and poor long-term survival, Dr. Cooper added.

Up to 24 patients with advanced CD19+ leukemias and lymphomas who have relapsed after allogeneic BMT will be enrolled in this investigator-initiated trial (NCT03579888). The primary endpoint of the study is to determine the safety and maximum tolerated dose of donor-derived genetically modified CD19-specific T cells manufactured using the RPM process. An additional study is planned through Ziopharms joint venture with Eden BioCell to evaluate the RPM technology using patient-derived (autologous) CD19-specific CAR-T in Greater China.

Research reveals three-year survival for adults with CD19+ acute lymphoblastic leukemia after allogeneic BMT ranges from 30% to 65%.1 For patients with other CD19+ cancers, allogeneic BMT can provide three-year survival rates between 30% to 75%.1 Few patients experience a durable remission following allogeneic BMT, regardless of the treatment modality, with some having a median survival of only 2 to 3 months.2

About Ziopharm Oncology, Inc.Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the bodys immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharms pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic collaborations with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Regeneron Pharmaceuticals. For more information, please visit http://www.ziopharm.com.

Forward-Looking Statements DisclaimerThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the progress, design and timing of the Company's research and development programs, the potential benefits of the Companys therapies, and the Companys expectations regarding the number of patients in its clinical trials. Although Ziopharms management team believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Ziopharm, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, changes in our operating plans that may impact our cash expenditures, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Ziopharms product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies and for which indication; the strength and enforceability of Ziopharms intellectual property rights; competition from other pharmaceutical and biotechnology companies as well as risk factors discussed or identified in the public filings with the Securities and Exchange Commission made by Ziopharm, including those risks and uncertainties listed in Ziopharms Quarterly Report on Form 10-Q filed by Ziopharm with the Securities and Exchange Commission. We are providing this information as of the date of this press release, and Ziopharm does not undertake any obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

Investor Relations Contacts:Ziopharm Oncology:Chris TaylorVP, Investor Relations and Corporate CommunicationsT: 617.502.1881E: ctaylor@ziopharm.com

LifeSci Advisors:Mike MoyerManaging DirectorT: 617.308.4306E: mmoyer@lifesciadvisors.com

Media Relations Contact:LifeSci Communications:Patrick BurseyT: 646.876.4932E: pbursey@lifescicomms.com

1 D'Souza A, Fretham C. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides, 2018. Available at https://www.cibmtr.org

2 Keil F, Prinz E, Kalhs P, et al. Treatment of leukemic relapse after allogeneic stem cell transplantation with cytotoreductive chemotherapy and/or immunotherapy or second transplants. Leukemia 2001; 15:355-361.

Read more:
Ziopharm Oncology Announces Initiation of Phase 1 Trial Evaluating Rapid Personalized Manufacturing CAR-T Technology in Patients with Relapsed CD19+...

Bone Marrow Stem Cells Comments Off on Ziopharm Oncology Announces Initiation of Phase 1 Trial Evaluating Rapid Personalized Manufacturing CAR-T Technology in Patients with Relapsed CD19+… | July 10th, 2020

Embryonic stem cells. The ethical issues associated with stem cell research could be resolved through the use of induced pluripotent stem cells, which are derived from fully committed and differentiated cells of the adult body

The almost miraculous benefits that stem cells may one day deliver have long been speculated on. Capable of becoming different types of cells, they offer huge promise in terms of transplant and regenerative medicine. It is, however, also a medical field that urges caution one that must constantly battle exaggeration. If stem cells do in fact hold the potential to reverse the ageing process, for example, then such breakthroughs remain many years away.

Recently, though, the field has had cause for excitement. In 2006, Japanese researcher Shinya Yamanaka discovered that mature cells could be reprogrammed to become pluripotent, meaning they can give rise to any cell type of the body. In 2012, the discovery of these induced pluripotent stem cells (iPSCs) saw Yamanaka and British biologist John Gurdon awarded the Nobel Prize in Physiology or Medicine. Since then, there has been much talk regarding the potential iPSCs possess, not only for the world of medicine, but for society more generally, too.

A big stepHistorically, one of the major hurdles preventing further research into stem cells has been an ethical one. Until the discovery of iPSCs, embryonic stem cells (ESCs) represented the predominant area of research, with cells being taken from preimplantation human embryos. This process, however, involves the destruction of the embryo and, therefore, prevents the development of human life. Due to differences in opinion over when life is said to begin during embryonic development, stem cell researchers face an ethical quandary.

The promise of significant health benefits and new revenue streams has led some clinics to offer unproven stem cell treatments to individuals

With iPSCs, though, no such dilemmas exist. IPSCs are almost identical to ESCs but are derived from fully committed and differentiated cells of the adult body, such as a skin cell. Like ESCs, iPSCs are pluripotent and, as they are stem cells, can self-renew and differentiate, remaining indefinitely propagated and retaining the ability to give rise to any human cell type over time.

One important distinction to make is that both ESCs and iPSCs do not exist in nature, Vittorio Sebastiano, Assistant Professor (Research) of Obstetrics and Gynaecology (Reproductive and Stem Cell Biology) at Stanford Universitys Institute for Stem Cell Biology and Regenerative Medicine, told The New Economy. They are both beautiful laboratory artefacts. This means that at any stage of development, you cannot find ESCs or iPSCs in the developing embryo, foetus or even in the postnatal or adult body. Both ESCs and iPSCs can only be established and propagated in the test tube.

The reason neither ESCs nor iPSCs can be found in the body is that they harbour the potential to be very dangerous. As Sebastiano explained, these cells could spontaneously differentiate into tumorigenic masses because of their intrinsic ability to give rise to any cell type of the body. Over many years of research, scientists have learned how to isolate parts of the embryo (in the case of ESCs) and apply certain culture conditions that can lock cells in their proliferative and stem conditions. The same is true for iPSCs.

To create iPSCs, scientists take adult cells and exogenously provide a cocktail of embryonic factors, known as Yamanaka factors, for a period of two to three weeks. If the expression of such factors is sustained for long enough, they can reset the programme of the adult cells and establish an embryonic-like programme.

Turning back the clockThere is already a significant body of research dedicated to how stem cells can be used to treat disease. For example, mesenchymal stem cells (usually taken from adult bone marrow) have been deployed to treat bone fractures or as treatments for autoimmune diseases. It is hoped that iPSCs could hold the key for many more treatments.

Global stem cell market:25.5%Expected compound annual growth rate (2018-24)$467bnExpected market value (2024)

IPSCs are currently utilised to model diseases in vitro for drug screening and to develop therapies that one day will be implemented in people, Sebastiano explained. Given their ability to differentiate into any cell type, iPSCs can be used to differentiate into, for example, neurons or cardiac cells, and study specific diseases. In addition, once differentiated they can be used to test drugs on the relevant cell type. Some groups and companies are developing platforms for cell therapy, and I am personally involved in two projects that will soon reach the clinical stage.

Perhaps the most exciting prospects draw on iPSCs regenerative properties. Over time, cells age for a variety of reasons namely, increased oxidative stress, inflammation and exposure to pollutants or sunlight, among others. All these inputs lead to an accumulation of epigenetic mistakes those that relate to gene expression rather than an alteration of the genetic code itself in the cells, which, over time, results in the aberrant expression of genes, dysfunctionality at different levels, reduced mitochondrial activity, senescence and more besides. Although the epigenetic changes that occur with time may not be the primary cause of ageing, the epigenetic landscape ultimately affects and controls cell functionality.

What we have shown is that, if instead of being expressed for two weeks we express the reprogramming factors for a very short time, then we see that the cells rejuvenate without changing their identity, Sebastiano said. In other words, if you take a skin cell and express the reprogramming genes for two to four days, what you get is a younger skin cell.

By reprogramming a cell into an iPSC, you end up with an embryonic-like cell the reprogramming erases any epigenetic errors. If expressed long enough, it erases the epigenetic information of cell identity, leaving embryonic-like cells that are also young.

Slow and steadyAs with any scientific advancement, financial matters are key. According to Market Research Engine, the global stem cell market is expected to grow at a compound annual growth rate of 25.5 percent between 2018 and 2024, eventually reaching a market value of $467bn. The emergence of iPSCs has played a significant role in shaping these predictions, with major bioscience players, such as Australias Mesoblast and the US Celgene, working on treatments involving this particular type of stem cell.

The business potential around stem cell research is huge, Sebastiano told The New Economy. [Particularly] when it comes to developing cell banks for which we have detailed genetic information and, for example, studying how different drugs are toxic or not on certain genetic backgrounds, or when specific susceptibility mutations are present.

Unfortunately, even as the business cases for iPSC treatments increase, a certain degree of caution must be maintained. The promise of significant health benefits and new revenue streams has led some clinics to offer unproven stem cell treatments to individuals. There have been numerous reports of complications emerging, including the formation of a tumour following experimental stem cell treatment in one particular patient, as recorded in the Canadian Medical Association Journal last year. Such failures risk setting the field back years.

The challenge for researchers now will be one of balance. The potential of iPSCs is huge both in terms of medical progress and business development but can easily be undermined by misuse. Medical advancements, particularly ones as profound as those associated with iPSCs, simply cannot be rushed.

Original post:
Could induced pluripotent stem cells be the breakthrough genetics has been waiting for? - The New Economy

Skin Stem Cells Comments Off on Could induced pluripotent stem cells be the breakthrough genetics has been waiting for? – The New Economy | July 10th, 2020

New HCPCS Code Enables Facility Reimbursement to Physician Offices Performing Skin Graft Substitute Procedures, Benefiting Wound Patients

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Merakris Therapeutics, LLC., a leader in innovative approaches for cutaneous wound healing, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned a Healthcare Common Procedure Coding System (HCPCS) product code Q4248 for its topical skin graft substitute, Dermacyte Matrix. The new HCPCS code, effective July 1, 2020, enables physician office reimbursement under Medicare Part B. Dermacyte Matrix is a crosslinked amniotic membrane allograft designed for cutaneous wound applications, commonly used by outpatient surgical, podiatry and dermatology clinics. Dermacyte is available in dehydrated and hydrated configurations with 5 years of shelf stability at room temperature.

This is another milestone for Merakris Therapeutics that the largest healthcare payer, CMS, has recognized Dermacyte Matrix with a unique reimbursement code. This strengthens our position with broader payer coverage for Dermacyte Matrix, says Chris Broderick, CEO of Merakris. We are dedicated to continued leadership in cell-free biologics and have aligned with academic institutions to support its product development and commercial operations while retaining full rights to our intellectual property.

Merakris has developed a novel purification system yielding two separate amniotic biomolecule fractions, one capable of promoting early-stage cutaneous wound healing, and the second fraction promoting late stage wound healing, including epithelialization and re-keratinization. Dr. W. Sam Fagg, MSc., PhD says this technology distinguishes our value proposition to physicians and payers. Merakris has successfully combined these with Dermacyte Matrix to demonstrate improved healing outcomes in cutaneous ulcers. Pursuant to recent FDA guidance, Merakris has completed a pre-IND meeting with the FDA and is preparing an IND to further develop the use of this technology in combination with Dermacyte Matrix.

About Merakris Therapeutics, LLC

Merakris Therapeutics, based in Research Triangle Park, North Carolina, is focused on researching, developing, and actively marketing regenerative healthcare products for wound care, ophthalmology, pain management, and skin rejuvenation. Our vision is to improve global patient care by pioneering commercially scalable biotherapeutic technologies primarily derived from perinatal cells and tissues. The company has filed patents to protect its amniotic fractionation technology, and a novel stem cell co-culture technology that produces an amniotic fluid-like solution targeted for scalable manufacturing for various therapies.

For more information contact Matt Murray at mmurray@merakris.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005591/en/

Read more from the original source:
Merakris Therapeutics, LLC Announces the Commercial Launch of Dermacyte Matrix and CMS Assignment of an HCPCS Code for Use as a Skin Graft Substitute...

Skin Stem Cells Comments Off on Merakris Therapeutics, LLC Announces the Commercial Launch of Dermacyte Matrix and CMS Assignment of an HCPCS Code for Use as a Skin Graft Substitute… | July 10th, 2020

Remember Owen Buell of Joliet, the toddler who was diagnosed with a neuroblastoma right before the COVID-19 pandemic began?

His abdomen had doubled in size and his eye looked bruised and was drooping, the story also said.

Since his diagnosis, Owen's had chemotherapy and abdominal surgery to remove a large tumor that had wrapped itself around major blood vessels.

And Tuesday night, Owen, who wont even turn 2 until Aug. 10, had the first of two stem cell treatments.

His health care team is hoping will help to address the hot spots in some of his bones his shoulders and one of his shins places chemo struggles to reach, according to his great-grandmother Jackie Moore of Florida.

The big thing yesterday is that he had very high blood pressure, Moore said. But sometimes thats from too much hydrationonce they put that IV in, he had tons of fluid.

But the family, which includes his parents Brian Buell and Valerie Mitchell, along with his brothers Elliott, age 8, and Bentley, age 5, still needs financial help.

Although the GoFundMe account has raised $20,000 of its $30,000 goal, donations have stalled, Moore said, but the familys needs are still so high.

Brian and Val are exhausted," Moore wrote on the Help for Baby Owen Buell Facebook page. "Val has the weight of the world on her shoulders and it shows on her face. Brian has done so much.

"Now after almost 5 months he is able to give Val a day off from the hospital. Otherwise, they have been there 24/7 with Owen. There are no volunteers right now because of the Covid virus."

No one is working right now and the familys van has taken a toll with the continual trips to Ann & Robert H. Lurie Children's Hospital of Chicago.

The medical bills for all this care has gone over a million dollars, Moore wrote on the Help for Baby Owen Buell Facebook page. Just one of Owen's shots is $6,000.

On top of the financial worries, Owens chemotherapy treatments have been very rough, Jackie said. When his platelet count would plummet, he went to the hospital for transfusions, she added.

Owen requires frequent diaper changes because the chemotherapy is so acid it can burn his skin, Moore said, so his parents have a special cream to use, too.

Doctors could not remove the part of Owens tumor that had wrapped itself around his major blood vessels, Moore said.

They literally would have scraped them off the blood vessels. It was too risky, Moore said. They could have nicked one of those blood vessels and he could have had a major bleed.

Owen required a special chemotherapy before the stem cell transplant. And then he had to be submerged in water every six hours to reduce the likelihood of welts, a reaction from this type of chemo, Moore said.

Sometimes he complains his leg is hurting, Moore said. But he never says his head hurts from the chemotherapy or that he is going to throw up because he doesnt have enough vocabulary for it yet, she added.

He simply throws up.

A nasogastric tube makes it difficult for Owen to eat.

And still he smiles, Moore said. Sometimes not the biggest of smiles.

But about 2 million stem cells were harvested from Owens body. He will stay in the hospital for a month and a parent can remain with him. Then Owen will go to a Ronald McDonald House for two weeks because he will need to stay close to the hospital, Moore said.

And then Owen will repeat the process: two rounds of potent chemo, a second stem cell transplant, a month-long stay in the hospital and two weeks at Ronald McDonald House, Moore said.

Hes at the point where he knows something is wrong, Jackie said. But you cant sit him down like you could to even an 8-year-old and say, Youve got this thing that wants to hurt your body.

People can donate to the GoFundMe page at bit.ly/2S7sPN7 or visit the Help for Baby Owen Buell and His Family Facebook page for updates and detailed instructions on other ways to help the family.

Read the original post:
Whatever happened to baby Owen? - The Herald-News

Skin Stem Cells Comments Off on Whatever happened to baby Owen? – The Herald-News | July 10th, 2020

Plasma transfers exercise benefit in mice

Exercise has a broad range of beneficial healthful effects. Horowitz et al. tested whether the beneficial effects of exercise on neurogenesis in the brain and improved cognition in aged mice could be transferred in plasma (blood without its cellular components) from one mouse to another (see the Perspective by Ansere and Freeman). Indeed, aged mice that received plasma from young or old mice that had exercised showed beneficial effects in their brains without hitting the treadmill. The authors identified glycosylphosphatidylinositol-specific phospholipase D1 as a factor in plasma that might, in part, mediate this favorable effect.

Science, this issue p. 167; see also p. 144

Reversing brain aging may be possible through systemic interventions such as exercise. We found that administration of circulating blood factors in plasma from exercised aged mice transferred the effects of exercise on adult neurogenesis and cognition to sedentary aged mice. Plasma concentrations of glycosylphosphatidylinositol (GPI)specific phospholipase D1 (Gpld1), a GPI-degrading enzyme derived from liver, were found to increase after exercise and to correlate with improved cognitive function in aged mice, and concentrations of Gpld1 in blood were increased in active, healthy elderly humans. Increasing systemic concentrations of Gpld1 in aged mice ameliorated age-related regenerative and cognitive impairments by altering signaling cascades downstream of GPI-anchored substrate cleavage. We thus identify a liver-to-brain axis by which blood factors can transfer the benefits of exercise in old age.

View post:
Blood factors transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain - Science Magazine

Skin Stem Cells Comments Off on Blood factors transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain – Science Magazine | July 10th, 2020

Written by Jayashree Narayanan | Pune | Updated: July 9, 2020 6:38:55 pm Lifestyle coach Luke Coutinho on dry fasting and why it matters for your body. (Source: PR Handout)

Dry fasting for good health has raised eyebrows for its complete abstinence from food and water for an extended period, but the trend has been presented as a superior form of fasting and cleansing by Luke Coutinho in his book The Dry Fasting Miracle: From Deprive to Thrive, published by Penguin Random House India.

Coutinho, a holistic lifestyle coach-integrative medicine, who has co-authored the book with Sheikh Abdul Aziz Nuaimi aka Green Sheikh, from UAEs Ajman royal family, advocates dry fasting and intermittent fasting for healthy living. He talks to indianexpress.com on the book, why fasting is for everyone, and how it could be a way to build immunity given the pandemic concerns.

Excerpts:

Why do you think fasting is important?

Fasting in earlier times was built into ones lifestyle; people ate early because there was hardly any light after sunset and their next meal would only be after sunrise. This practice spread to all religions as a discipline due to its health and spiritual benefits. Sickness too was followed by fasting, because it allowed the body to redirect its energy towards healing and repairing. So, fasting is very natural to us, however, we have moved too far away from this concept because of the habit of constant nibbling, an abundance of food and storage options, etc. Our bodies were never designed to eat the amount of food we actually eat today. Overeating turns out to be one of the most common causes of sickness, more so when the quality of food is bad and inappropriate.

Today, science is proving how necessary fasting is for the immune system, digestive system, energy, spirituality, cardiovascular health, obesity, mental health and so much more.

Fasting draws up an image of no food, no water, and basically starving. How is dry fasting different?

Fasting is not starvation. Fasting is not deprivation. Fasting is a discipline where one willingly gives their body and digestive system a break, redirecting the energy towards rejuvenation and detoxification. Fasting is way more disciplined and planned. Skipping meals is not fasting.

Fasting must be practiced around the same time, so our body builds a memory around when it can expect food. Starvation can lead to nutritional deficiencies and acidity, whereas a well-planned fasting schedule eradicates acidity.

Isnt it dangerous for the body to go without food and, more importantly, water for more than 12 hours?

Dry fasting is a cleansing practice that involves complete abstinence from food and water (in any form) for a brief period of time, which could range from 10 hours to 16, 18, 20 hours, depending upon an individuals comfort level.

Our digestive system utilises almost 80 per cent of the energy into digestion, absorption and assimilation with 20 per cent of the energy towards healing, repair, recovery, growth, rejuvenation, detoxification and building the immune system. Too much eating, eating at the wrong timings, overeating can all drain energy, leaving little or no energy for repair and recovery. Fasting gives the digestive system a temporary shutdown, boosting the immune system, stem cell regeneration, hormonal balance, etc.

Dry fasting also sends our body into the autophagy mode (prolonged fasting) wherein its intelligence sacrifices the sickest cells and activates stem cell regeneration. All of this and more can be achieved through fasting, provided its done the right way.

Of course, if someone has a medical condition and cannot fast, they must refrain or modify it according to what their health experts recommend. For example, dry fasting may not suit someone with recurrent UTI infection, so he/she may adopt intermittent fasting. Or someone on water restriction may not be able to do intermittent fasting and can take short fasts under expert guidance only.

Interestingly, the book also mentions hard dry fasting, which means absolutely no contact with water, not just consumption of it but also bathing, washing or cleaning. Is it possible?

Yes, for a brief period of time. Also, hard dry fasting is intense, so its a personal choice whether one is comfortable with fasting by not washing hands, bathing, brushing, or handling water. Not many people are because they go to offices and travel or work and that is absolutely fine. Soft dry fasting (which includes brushing, bathing, etc) if done the right way is powerful in itself.

Fasting is viewed from a religious angle. But in the book, you mention, it is more than that. Can you elaborate?

Fasting does have religious and spiritual significance but its benefits extend beyond that. In fact, it improves the health of an individual from all dimensions physical, mental, emotional, intellectual as well as spiritual.

Fasting is also turning into another fad simply because it is used as a quick fix to achieve health goals, especially losing weight and belly fat.

Fasting is not a solution for weight gain. Use it to instill discipline with reference to eating and constant nibbling, start listening to your body.

Secondly, individuals try to complete with each other on fasting and the number of hours fasted. If someone is doing a 16-hour fast, everyone wants to do a 16 hour fast. Fasting is not a competition. Its what suits you. There is no magic number of hours one should fast.

Lastly, some people claim to be fasting but still have tea/coffee/juices, etc. Such an approach can be detrimental to ones health. Fasting is not a fad.

You mention that the human body is designed for fasting and the simplest way to begin is to have an early dinner. But, people rarely follow that and tend to even eat at odd hours. Is it healthy?

Times may have changed, but not the way the human body functions.While the wisdom of early dinner comes through our grandparents, today, science is proving how late-night meals mess up our digestion, immunity, blood sugar levels, weight, etc. The very fact that the pancreatic cells have melatonin receptors on them proves that our pancreas is meant to shut down when our body starts to secrete melatonin which is when the sun sets. A person who has had a late-night dinner would be able to answer how heavy and uncomfortable it could make one feel the next day and even during the course of the night. Even worse, if the dinner is heavy, because our body is just not designed to digest it at night.

By far, eating an early dinner which is as close to sunset is a powerful lifestyle change. It can result in better immunity, digestion, energy levels, better skin and hair, etc.

Considering each and everyones body systems are different, do you think dry fasting is everyone?

Absolutely. What do you lose by trying? Most people do not fear fasting, they resist moving out of their comfort zones. There are so many people who report literally magical benefits from fasting. If someone is in a dilemma, read about these inspiring stories.At the same time, fasting doesnt have to suit all. Also, if one form of fasting doesnt suit a person, for e.g. dry fasting, in case of a health condition like recurrent UTI, they can adopt intermittent fasting. In the end, its about what suits a person.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Books And Literature News, download Indian Express App.

IE Online Media Services Pvt Ltd

Read this article:
Fasting is not starvation or a fad, it is a discipline: Luke Coutinho - The Indian Express

Skin Stem Cells Comments Off on Fasting is not starvation or a fad, it is a discipline: Luke Coutinho – The Indian Express | July 10th, 2020

Global Stem Cell-Derived Cells market Research presents a Comprehensive scenario Which can be segmented according to producers, product type, applications, and areas. This segmentation will provide deep-dive analysis of the Stem Cell-Derived Cells business for identifying the growth opportunities, development tendencies and factors limiting the development of the marketplace. This report features forecast market information based on previous and present Stem Cell-Derived Cells industry scenarios and growth facets. Each of the Essential regions coated in Stem Cell-Derived Cells report are North America, Europe, Asia-Pacific, South America, Middle East and Africa. The Stem Cell-Derived Cells market share and market prognosis of every region from 2020-2027 are presented within this report. A deep study of Stem Cell-Derived Cells marketplace dynamics will help the market aspirants in identifying the business opportunities that will lead to accumulation of earnings. This segment can efficiently determine the Stem Cell-Derived Cells hazard and key market driving forces.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/28780

The Stem Cell-Derived Cells report is segmented to provide a clear and Precise view of this international Stem Cell-Derived Cells market statistics and market quotes. Stem Cell-Derived Cells report Information represented in the form of graphs, charts, and statistics will show the Stem Cell-Derived Cells growth rate, volume, goal customer analysis. This report presents the significant data to all Stem Cell-Derived Cells business aspirants which will facilitate useful business decisions.

key players in stem cell-derived cells market are focused on generating high-end quality cardiomyocytes as well as hepatocytes that enables end use facilities to easily obtain ready-made iPSC-derived cells. As the stem cell-derived cells market registers a robust growth due to rapid adoption in stem cellderived cells therapy products, there is a relative need for regulatory guidelines that need to be maintained to assist designing of scientifically comprehensive preclinical studies. The stem cell-derived cells obtained from human induced pluripotent stem cells (iPS) are initially dissociated into a single-cell suspension and later frozen in vials. The commercially available stem cell-derived cell kits contain a vial of stem cell-derived cells, a bottle of thawing base and culture base.

The increasing approval for new stem cell-derived cells by the FDA across the globe is projected to propel stem cell-derived cells market revenue growth over the forecast years. With low entry barriers, a rise in number of companies has been registered that specializes in offering high end quality human tissue for research purpose to obtain human induced pluripotent stem cells (iPS) derived cells. The increase in product commercialization activities for stem cell-derived cells by leading manufacturers such as Takara Bio Inc. With the increasing rise in development of stem cell based therapies, the number of stem cell-derived cells under development or due for FDA approval is anticipated to increase, thereby estimating to be the most prominent factor driving the growth of stem cell-derived cells market. However, high costs associated with the development of stem cell-derived cells using complete culture systems is restraining the revenue growth in stem cell-derived cells market.

The global Stem cell-derived cells market is segmented on basis of product type, material type, application type, end user and geographic region:

Segmentation by Product Type

Segmentation by End User

The stem cell-derived cells market is categorized based on product type and end user. Based on product type, the stem cell-derived cells are classified into two major types stem cell-derived cell kits and accessories. Among these stem cell-derived cell kits, stem cell-derived hepatocytes kits are the most preferred stem cell-derived cells product type. On the basis of product type, stem cell-derived cardiomyocytes kits segment is projected to expand its growth at a significant CAGR over the forecast years on the account of more demand from the end use segments. However, the stem cell-derived definitive endoderm cell kits segment is projected to remain the second most lucrative revenue share segment in stem cell-derived cells market. Biotechnology and pharmaceutical companies followed by research and academic institutions is expected to register substantial revenue growth rate during the forecast period.

North America and Europe cumulatively are projected to remain most lucrative regions and register significant market revenue share in global stem cell-derived cells market due to the increased patient pool in the regions with increasing adoption for stem cell based therapies. The launch of new stem cell-derived cells kits and accessories on FDA approval for the U.S. market allows North America to capture significant revenue share in stem cell-derived cells market. Asian countries due to strong funding in research and development are entirely focused on production of stem cell-derived cells thereby aiding South Asian and East Asian countries to grow at a robust CAGR over the forecast period.

Some of the major key manufacturers involved in global stem cell-derived cells market are Takara Bio Inc., Viacyte, Inc. and others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/28780

The Stem Cell-Derived Cells report cover following data points:

Part 1: This part enlists the global Stem Cell-Derived Cells marketplace Overview, covering the simple market debut, market analysis by kind, applications, and areas. Stem Cell-Derived Cells industry states and prognosis (2020-2027) is presented in this part. Additionally, Stem Cell-Derived Cells market dynamics saying the chances, market risk, and key driving forces are studied.

Part 2: This part covers Stem Cell-Derived Cells manufacturers profile based On their small business overview, product type, and application. Additionally, the sales volume, Stem Cell-Derived Cells product price, gross margin analysis, and Stem Cell-Derived Cells market share of every player is profiled in this report.

Part 3 and Part 4: This part presents the Stem Cell-Derived Cells competition Based on earnings, earnings, and market share of each producer. Part 4 covers the Stem Cell-Derived Cells market scenario based on regions. Region-wise Stem Cell-Derived Cells sales and growth (2015-2019) is studied in this report.

America and Europes Stem Cell-Derived Cells industry by countries. Under this Stem Cell-Derived Cells revenue, market share of those nations like USA, Canada, and Mexico is provided. Under Europe Stem Cell-Derived Cells report contains, the countries such as Germany, UK, France, Russia, Italy, Russia and their sales and growth is coated.

Part 7, Part 8 and Part 9: These 3 sections covers Stem Cell-Derived Cells The earnings and expansion in these regions are presented in this Stem Cell-Derived Cells industry report.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/28780

Part 10 and Part 11: This component depicts the Stem Cell-Derived Cells marketplace Share, earnings, sales by product type and application. The Stem Cell-Derived Cells sales growth seen during 2012-2020 is covered in this report.

Related to Stem Cell-Derived Cells market (2020-2027) for every region. The sales channels including indirect and direct Stem Cell-Derived Cells advertising, traders, distributors, and future trends are presented in this report.

Part 14 and Part 15: These components present Stem Cell-Derived Cells market key Research findings and judgment, research methodology, and data sources are covered.

Therefore, Global Stem Cell-Derived Cells report is a complete blend covering all The very important market aspects.

Continued here:
Stem Cell-Derived Cells Market is Projected to Reach US$XX by the end of 2019 2029 - 3rd Watch News

IPS Cell Therapy Comments Off on Stem Cell-Derived Cells Market is Projected to Reach US$XX by the end of 2019 2029 – 3rd Watch News | July 10th, 2020

The Skin Care Cosmetic market revenue was xx.xx Million USD in 2014, grew to xx.xx Million USD in 2018, and will reach xx.xx Million USD in 2024, with a CAGR of x.x% during 2019-2024. Based on the Skin Care Cosmetic industrial chain, this report mainly elaborates the definition, types, applications and major players of Skin Care Cosmetic market in details. Deep analysis about market status (2014-2019), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2019-2024), regional industrial layout characteristics and macroeconomic policies, industrial policy has also be included. From raw materials to downstream buyers of this industry will be analyzed scientifically, the feature of product circulation and sales channel will be presented as well. In a word, this report will help you to establish a panorama of industrial development and characteristics of the Skin Care Cosmetic market., The Skin Care Cosmetic market can be split based on product types, major applications, and important regions.

Download PDF Sample of Skin Care Cosmetic Market report @ https://www.arcognizance.com/enquiry-sample/740561

Major Players in Skin Care Cosmetic market are:, Avon Products Inc, Kao Corporation, Procter & Gamble, The Estee Lauder Companies Inc, Beiersdorf AG, Unilever PLC, The Body Shop International PLC, Johnson & Johnson, LOreal S.A.

Major Regions that plays a vital role in Skin Care Cosmetic market are:, North America, Europe, China, Japan, Middle East & Africa, India, South America, Others

Brief about Skin Care Cosmetic Market Report with [emailprotected] https://arcognizance.com/report/global-skin-care-cosmetic-industry-market-research-report

Most important types of Skin Care Cosmetic products covered in this report are:, Sensitive Skin Care, Dry Skin Care, Infants Skin Care, Others

Most widely used downstream fields of Skin Care Cosmetic market covered in this report are:, Stem Cells Protection Against UV, Flakiness Reduction, Rehydrate the Skin Surface, Minimize wrinkles, Increase the viscosity of Aqueous

There are 13 Chapters to thoroughly display the Skin Care Cosmetic market. This report included the analysis of market overview, market characteristics, industry chain, competition landscape, historical and future data by types, applications and regions.

Chapter 1: Skin Care Cosmetic Market Overview, Product Overview, Market Segmentation, Market Overview of Regions, Market Dynamics, Limitations, Opportunities and Industry News and Policies.

Chapter 2: Skin Care Cosmetic Industry Chain Analysis, Upstream Raw Material Suppliers, Major Players, Production Process Analysis, Cost Analysis, Market Channels and Major Downstream Buyers.

Chapter 3: Value Analysis, Production, Growth Rate and Price Analysis by Type of Skin Care Cosmetic.

Chapter 4: Downstream Characteristics, Consumption and Market Share by Application of Skin Care Cosmetic.

Chapter 5: Production Volume, Price, Gross Margin, and Revenue ($) of Skin Care Cosmetic by Regions (2014-2019).

Chapter 6: Skin Care Cosmetic Production, Consumption, Export and Import by Regions (2014-2019).

Chapter 7: Skin Care Cosmetic Market Status and SWOT Analysis by Regions.

Chapter 8: Competitive Landscape, Product Introduction, Company Profiles, Market Distribution Status by Players of Skin Care Cosmetic.

Chapter 9: Skin Care Cosmetic Market Analysis and Forecast by Type and Application (2019-2024).

Chapter 10: Market Analysis and Forecast by Regions (2019-2024).

Chapter 11: Industry Characteristics, Key Factors, New Entrants SWOT Analysis, Investment Feasibility Analysis.

Chapter 12: Market Conclusion of the Whole Report.

Chapter 13: Appendix Such as Methodology and Data Resources of This Research.

Some Point of Table of Content:

Chapter One: Skin Care Cosmetic Introduction and Market Overview

Chapter Two: Industry Chain Analysis

Chapter Three: Global Skin Care Cosmetic Market, by Type

Chapter Four: Skin Care Cosmetic Market, by Application

Chapter Five: Global Skin Care Cosmetic Production, Value ($) by Region (2014-2019)

Chapter Six: Global Skin Care Cosmetic Production, Consumption, Export, Import by Regions (2014-2019)

Chapter Seven: Global Skin Care Cosmetic Market Status and SWOT Analysis by Regions

Chapter Eight: Competitive Landscape

Chapter Nine: Global Skin Care Cosmetic Market Analysis and Forecast by Type and Application

Chapter Ten: Skin Care Cosmetic Market Analysis and Forecast by Region

Chapter Eleven: New Project Feasibility Analysis

Chapter Twelve: Research Finding and Conclusion

Chapter Thirteen: Appendix continued

List of tablesList of Tables and FiguresFigure Product Picture of Skin Care CosmeticTable Product Specification of Skin Care CosmeticFigure Market Concentration Ratio and Market Maturity Analysis of Skin Care CosmeticFigure Global Skin Care Cosmetic Value ($) and Growth Rate from 2014-2024Table Different Types of Skin Care CosmeticFigure Global Skin Care Cosmetic Value ($) Segment by Type from 2014-2019Figure Sensitive Skin Care PictureFigure Dry Skin Care PictureFigure Infants Skin Care PictureFigure Others PictureTable Different Applications of Skin Care CosmeticFigure Global Skin Care Cosmetic Value ($) Segment by Applications from 2014-2019Figure Stem Cells Protection Against UV PictureFigure Flakiness Reduction PictureFigure Rehydrate the Skin Surface PictureFigure Minimize wrinkles PictureFigure Increase the viscosity of Aqueous PictureTable Research Regions of Skin Care CosmeticFigure North America Skin Care Cosmetic Production Value ($) and Growth Rate (2014-2019)Figure Europe Skin Care Cosmetic Production Value ($) and Growth Rate (2014-2019)Table China Skin Care Cosmetic Production Value ($) and Growth Rate (2014-2019)Table Japan Skin Care Cosmetic Production Value ($) and Growth Rate (2014-2019)continued

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:Analytical Research Cognizance (ARC)is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential.ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:Ranjeet DengaleDirector SalesAnalytical Research Cognizance+1 (646) 403-4695, +91 90967 44448Email: [emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Read more here:
Impact Of COVID-19 On Skin Care Cosmetic Market 2020 Industry Challenges, Business Overview And Forecast Research Study 2024 - Owned

Skin Stem Cells Comments Off on Impact Of COVID-19 On Skin Care Cosmetic Market 2020 Industry Challenges, Business Overview And Forecast Research Study 2024 – Owned | July 8th, 2020

The studies show that JAK inhibitors and other small molecules are capable of reawakening dormant hair follicles and stem cell therapies that can develop new follicles.

The first study was led by Angela Christiano, whos a professor of Dermatology at Columbia University Vagelos College of Physicians and Surgeons. The researchers discovered some previously unknown cells that ensure that mouse hair follicles dont leave a resting state. If the activities of these cells are inhibited, dormant follicles can be reawakened.

In the second research, the team of Christiano found a method for growing human hair in a dish. This method could make more men and women start exploring the idea of hair restoration surgery. It could also enhance the method that pharmaceutical companies consider when looking for new hair-growth medications.

In pattern baldness, lots of hair follicles are still in existence. However, they are dormant. The focus of researchers on getting drugs that function effectively in the same pathways as minoxidil and finasteride has affected their quest to find new drugs that can reawaken follicles and inhibit hair growth. Notably, minoxidil and finasteride are the only two medications that can be used by men suffering from male pattern baldness.

The researchers had previously found a new pathway, known as JAK-STAT, which is active in the stem cells of resting hair follicles and makes them remain in a state of dormancy. Christiano and other researchers in his team showed that JAK inhibitors used on mouse skin are good for reawakening resting follicles in mice.

Their second study was targeted at knowing more about the natural processes of making sure that the follicles remain dormant. Therefore, the researchers searched for factors that managed the activity of the JAK pathway in the hair follicle.

During the search, the Colombian researchers found a formerly unknown immune-related cell type that is capable of creating a substance called Oncostatin M. This substance makes sure that the follicle doesnt leave a dormant state. One of the authors of the study, Etienne Wang, Ph.D., notes Rare subsets of immune cells were previously difficult to identify in a whole skin, but this work was facilitated by our ability to sequence individual cells and pinpoint the ones making Oncostatin M.

There are some resemblances between these cells and macrophages, which are regarded as the immune systems scavenger cells. The researchers discovered that these cells are close to resting hair follicles.

These cells have been named trichophages. It should be noted that this name is taken from tricho, which is a Greek word for hair.

Besides, the hair cycle could be turned on when the trichophages are being targeted. By utilizing antibodies and small molecular inhibitors for inhibiting Csf1R, which is a receptor that is found on the trichophages, the flow of Oncostatin M could be blocked so that the hair cycle can start once again.

The second study involved the creation of a means of growing human hair in a dish. This method could lead to hair restoration surgery for an increased number of individuals including women. This new development could also enhance the method through which pharmaceutical companies find new hair growth medications.

It is worthwhile to note that this study brings a novel idea of growing human hair follicles in a dish without using any implantation in the skin.

Notably, researchers have been generating new rat or mouse hairs by culturing cells that were extracted from the end of existing follicles.

To find a way around human hair cells resistance, the Colombian researchers have been looking for ways to build conditions that look like the 3D environment that is the habitat of human hair cells. Although they failed at the beginning, they are making progress now as they have found a way to grow new human hair follicles in a dish in a lab.

In a nutshell, these new approaches can bring a significant change to the process of dealing with hair loss in both men and women. While studies are still going on, you can cope with your hair loss by picking the right products at Lilyhair.co.uk to improve your overall look.

Continue reading here:
Studies uncover new approaches to combat hair loss in men and women - Business MattersBusiness Matters

Skin Stem Cells Comments Off on Studies uncover new approaches to combat hair loss in men and women – Business MattersBusiness Matters | July 8th, 2020

Stem cells have been holding great promise for regenerative medicine for ages. In the last decade, many studies have revealed this form of cell, which in Spanish is calledmother cell due to its ability to contribute to various different cell types, may be applied in regenerative medicine to diseases such as muscle and nervous system disorders, among others.

Scientists and stem cell leaders Sir John B. Gurdon and Shinya Yamanaka received the Nobel Prize in Physiology and Medicine in 2012 for this idea.

However, one of the key constraints in the application of these herbal remedies is the caliber of the stem cells that may be made in the lab, which impedes their use for curative purposes.

Currently, a team in the Cell Division and Cancer Group of the Spanish National Cancer Research Centre (CNIO), headed by researcher Marcos Malumbres, has recently developed a fresh, easy and fast technology that enhances in vitro and in vivo the possibility of stem cells to differentiate into adult cells. The study results will be released this week in The EMBO Journal.

In recent years, several protocols have been proposed to obtain reprogrammed stem cells in the laboratory from adult cells, but very few to improve the cells we already have.The method we developed is able to significantly increase the quality of stem cells obtained by any other protocol, thus favouring the efficiency of the production of specialised cell types.Mara Salazar-Roa, Study First Author and Researcher, Centro Nacional de Investigaciones Oncolgicas

Roa is likewise the co-corresponding author of this analysis.

Within this study, the researchers identified an RNA sequence, called microRNA 203, that can be found at the earliest embryonic stages before the embryo implants in the uterus and when stem cells have their highest ability to generate all the different cells.When they added this molecule to stem cells from the laboratory, they discovered that the cells ability to convert into other cell types improved appreciably.

To corroborate them, they used stem cells of both human and murine origin, and of genetically altered mice. The results were so spectacular, both in mouse cells and in human cells

Application of the microRNA for just 5 days boosts the potential of stem cells in most situations we tested and improves their ability to become other specialised cells, even months after being connected with the microRNA. Says Salazar-Roa.

According to the research, cells modified by this new protocol are more efficient in generating functional cardiac cells, opening the doorway to a better generation of different cell types essential for the cure of degenerative disorders.

Malumbres, mind of the CNIO Cell and Cancer Division Group, states:To deliver this asset to the clinic, cooperation with labs or companies that are looking to exploit that technology is now essential in each particular case.

In this circumstance, Salazar-Roa recently participated, in close collaboration with all the CNIOs Innovation group, in prestigious creation programs like IDEA2 International of the Massachusetts Institute of Technology (MIT) and also CaixaImpulse of thisLa Caixa Foundation, where they also obtained funding to start the maturation of the technology.

See more here:
New technology May Raise the quality of stem cells Found in regenerative medicine - Microbioz India

Cardiac Stem Cells Comments Off on New technology May Raise the quality of stem cells Found in regenerative medicine – Microbioz India | July 8th, 2020

New Jersey, United States,- Market Research Intellect sheds light on the market scope, potential, and performance perspective of the Global Medicinal Fungi Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the global Medicinal Fungi market.

The research study includes the latest updates about the COVID-19 impact on the Medicinal Fungi sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Medicinal Fungi manufacturers/companies operating at both regional and global levels:

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=212882&utm_source=3WN&utm_medium=888

The Medicinal Fungi market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Medicinal Fungi market.

This study analyzes the growth of Medicinal Fungi based on the present, past and futuristic data and will render complete information about the Medicinal Fungi industry to the market-leading industry players that will guide the direction of the Medicinal Fungi market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Medicinal Fungi market. Additionally, it includes a share of each segment of the Medicinal Fungi market, giving methodical information about types and applications of the market.

Reasons for Buying Medicinal Fungi Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Medicinal Fungi market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.marketresearchintellect.com/need-customization/?rid=212882&utm_source=3WN&utm_medium=888

In the end, the Medicinal Fungi market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the global Medicinal Fungi market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Yohimbine Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Zeaxanthine Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Zeolite Powder Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Zeolites Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Zinc Acetylacetonate Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Visit link:
Medicinal Fungi Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News

Cardiac Stem Cells Comments Off on Medicinal Fungi Market Growth By Manufacturers, Type And Application, Forecast To 2026 – 3rd Watch News | July 8th, 2020

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Hematopoietic Stem Cells Transplantation Market which would mention How the Covid-19 is affecting the Hematopoietic Stem Cells Transplantation Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Hematopoietic Stem Cells Transplantation Players to Combat Covid-19 Impact.

Hematopoietic stem cell transplantation (HSCT) includes the intravenous infusion of autologous or allogeneic stem cells composed from bone marrow, or umbilical cord blood, peripheral blood to reestablish hematopoietic purpose in patients whose bone marrow or immune system is dented or flawed.

Request for sample report:

https://www.reportconsultant.com/request_sample.php?id=70734

Report Consultant has recently added a new Report on Hematopoietic Stem Cells Transplantation Market into its largest Database. It gives the complete report on trends, growth, and opportunity, restraint. Along with this, it delivers a comprehensive description of the key players of different regions.

Leading Players Hematopoietic Stem Cells Transplantation Market:

Escape Therapeutics, Lonza Group, Regen BioPharma Inc, Cesca Therapeutics Inc., Cryo-Save AG, CBR Systems, Inc., Pluristem Therapeutics Inc., China Cord Blood Corporation, and ViaCord Inc.

It contains an enormous database containing numerous market segments and sub-segments. The study also provides importance on the latest daises along with the effect of certain platforms on market growth.

Ask for Discount on This Report:

https://www.reportconsultant.com/ask_for_discount.php?id=70734

Market Segmentation: The market is segmented on the basis of type, application, and region.

Market Segmentation by Type:

Market Segmentation by Application:

Market Segmentation by Regions:

To achieve this, the Report Consultant has given prime importance to the exploration techniques for global clients and potential clients. Reaching out towards global clients has become a vital part to succeed in the Hematopoietic Stem Cells Transplantation Market. It offers SWOT analysis to identify the various significant business parameters such as strengths, weaknesses, threats, and opportunities which support to decision-makers to formulate the data-driven decisions in businesses.

Buy an exclusive Report:

https://www.reportconsultant.com/checkout?id=70734

Reasons for buying this research report:

About us:

Report Consultant A global leader in analytics, research, and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly. We make sense of drawbacks, opportunities, circumstances, estimations, and information using our experienced skills and verified methodologies.

Our research reports will give you an exceptional experience of innovative solutions and outcomes. We have effectively steered businesses all over the world with our market research reports and are outstandingly positioned to lead digital transformations. Thus, we craft greater value for clients by presenting advanced opportunities in the global market.

Contact us:

Rebecca Parker

(Report Consultant)

Contact No: +81-368444299

[emailprotected]

http://www.reportconsultant.com

Read the original:
Thriving Growth of Hematopoietic Stem Cells Transplantation Market Forecast 2020 with leading players Escape Therapeutics, Lonza Group, Regen...

Bone Marrow Stem Cells Comments Off on Thriving Growth of Hematopoietic Stem Cells Transplantation Market Forecast 2020 with leading players Escape Therapeutics, Lonza Group, Regen… | July 8th, 2020

LONDON, July 6, 2020 /PRNewswire/ -- IVIRMA, a global network of fertility clinics and world-leading pioneer in fertility research, are presenting a breakthrough study at the 36th Congress of the European Society of Human Reproduction and Embryology (ESHRE) today, demonstrating the possibility of 're-awakening' the ovaries in women under 40 (38 years and below) with the lowest reproductive reserve at the ovarian level.1 The ASCOT technique (involving infusion of stem cells in the ovarian artery), which has recently been shown to be successful in low-responder patients, has now shown it can achieve pregnancy in a woman with premature ovarian failure (POF).1

The study, 'Bone marrow derived stem cells restore ovarian function and fertility in premature ovarian insufficiency women. Interim report of a randomized trial: mobilization versus ovarian injection',1 which is still ongoing, includes two study arms: one using the ASCOT technique, that is, the infusion of stem cells in the ovarian artery* and, second, a less invasive option consisting of mobilising the stem cells, and allowing them to reach the ovaries through the bloodstream directly. The preliminary results have shown that ovarian follicle development was achieved in both groups, with some patients re-starting menstruation, and a decrease in menopausal symptoms. As a result of this procedure, embryos were obtained in 2 out of the 10 participants, and even one pregnancy through the ASCOT technique was achieved.

Dr. Diaz, Medical Director, IVI London, a leading fertility specialist and co-pioneer of the world's first womb transplant, commented, "We are truly excited by these very promising results achieving ovary re-awakening and pregnancy using stem cells in a woman who previously may not have had the option to conceive using her own eggs. We continually strive to pioneer on the cutting-edge of fertility research, as we know how harrowing it can be for every person struggling to conceive. These new techniques may give us potential new options for women with premature ovarian failure, in addition to those with low ovarian reserve."

It is estimated that 1 in 100 women under 40 years of age suffer from premature ovarian failure (POF) in the UK. 2.5% of all patients with POF are adolescents.2 This premature cessation of ovarian activity is one of the most challenging scenarios in terms of reproduction and can be devastating. Now, thanks to the findings of this study, led by Dr. Sonia Herraiz, researcher at the IVI Foundation-IIS la Fe, Spain and Dr. Nuria Pellicer, gynaecologist at Hospital la Fe in Valencia, Spain, there might be hope for women suffering from this fertility issue.

Dr. Nuria Pellicer, Gynaecologist, Hospital la Fe, Valencia, Spain added, "So far, we obtained embryos in 2 of the 10 patients included and one 37-week pregnancy in the ASCOT arm, in patients with almost no chance of successful pregnancy with classic in vitro fertilisation procedures. We found that both arms promoted the development of follicles, and some patients have even recovered their menstruation, thus reducing menopausal symptoms However, these are preliminary results of an ongoing study, so we remain cautious until the study is complete. We aim to develop a technique that is as minimally invasive as possible over time and standardise it so that it can be implemented in all our clinics. We would like to make it possible to offer any woman who wishes to become a mother the possibility of doing so, even when her reproductive circumstances are unfavourable."

"This is a very encouraging line of research in which we will continue to work with a single goal: to improve assisted reproduction techniques and treatments in order to obtain the best results, however difficult the reproductive prognosis may seem," concluded Dr. Herraiz, researcher at the IVI Foundation-IIS, la Fe, Spain.

More About the Study1

In addition to this research, IVI are presenting three more studies at the ESHRE Congress:

These new techniques and other research conducted by IVI is translated and applied to the treatments available in their clinics across the world, which is in turn reflected in the achieved results. The London clinic has achieved 71.4% clinical pregnancy rates per embryos transferred in women under the age of 386 and recent data shows that with PGT-A genetic screening the evolutive pregnancy rate is 57% in women undergoing treatment at IVI London as compared to the national average of 42%.7 Furthermore, 100% of these pregnancies have been achieved through single embryo transfer, eliminating chances of multiple pregnancy and the complications that arise with it.7

More about the ASCOT technique development: 3 babies and 6 pregnancies achieved so far in low-responder patients

To date, 3 babies and 6 pregnancies have been achieved using the ASCOT technique for ovarian rejuvenation in low-responder patients with low ovarian reserve, pioneered by IVIRMA Global. The technique involves transplanting bone marrow-derived stem cells (BMDSC) into the ovarian artery, achieving a partial reversal of ageing of the ovary, the organ responsible for ovulation, and activating the dormant follicles that would otherwise remain arrested in the ovary. After its first phase in animal models to test the effectiveness of the technique with stem cells, this study went to its second phase in low-responder patients. A total of 20 patients had their stem cells mobilized, extracted from peripheral blood and implanted back into the ovary in order to reverse the ageing process and activate the dormant follicles. This technique has improved ovarian function biomarkers in 81% of low responder patients. In addition, spontaneous pregnancies occurred. In view of the success of this phase, the next stage was undertaken, which consisted of recruiting women under 38 years of age, this time with early ovarian failure (a situation with a worse reproductive prognosis that of low responders). From here the above-mentioned study arose.

IVIRMA Global and IVI London, UK

IVI was founded in 1990, as the first medical institution in Spain fully dedicated to Assisted Reproduction. Since then it has helped with the birth of more than 200,000 babies thanks to the application of the latest Assisted Reproduction technologies. In early 2017, IVI merged with RMANJ, becoming the largest Assisted Reproduction group in the world. It currently has more than 65 clinics in 9 countries and is the leading centre for Reproductive Medicine. In 2016 IVI opened its doors in London, located in the heart of the medical district.www.rmanetwork.comhttps://ivi-fertility.co.uk/

References

Logo - https://mma.prnewswire.com/media/1200377/IVI_Logo.jpg

Read more here:
Breakthrough study demonstrates the 're-awakening' of the ovaries and achieves pregnancy in woman with premature ovarian failure using stem cells -...

Bone Marrow Stem Cells Comments Off on Breakthrough study demonstrates the ‘re-awakening’ of the ovaries and achieves pregnancy in woman with premature ovarian failure using stem cells -… | July 8th, 2020

One cancer survivor looks at all the ways they might have gotten cancer, and wonders if any of those risk factors will factor into recurrence.

William Ramshaw resides in the expansive Pacific Northwest. He is a six-year survivor of pancreatic cancer and has written a memoir Gut Punched! Facing Pancreatic Cancer.

So, what would someone do to get cancer?

Use tobacco. Both my parents smoked packs a day. My brother chews. One of my best friends chain-smoked. I used to tell him, Dennis, this is going to kill you. He laughed. It did. Lost to esophageal cancer. Given those ominous Surgeon Generals Warnings, all caps and bolded, along with horrendous TV infomercials, I am mystified why people still use tobacco, but they do. Nicotine addiction is an awful thing.

Being overweight. Ok, this one is closer to home. Before getting pancreatic cancer, I had been a big guy. Not blimp-sized mind you but carrying pounds I didnt need. Post-surgery, I lost a third of my body weight, about 100 pounds. I have no butt. Yes, I can now wear those skinny jeans. Also, due to being replumbed, I cant even gain weight. Still, I wouldnt recommend my weight loss program to anyone. Its barbaric.

Getting too much sun. Growing up I plowed our orchard in my cutoffs with no shirt. By the end of summer, I was toasted brown. Looking back, I hope the layer of dirt shielded me from getting too many rays. Excess UV light is known to cause skin cancer. So far so good. I dont have any skin lesions yet.

Exposure to bad stuff. It seems everything I buy anymore comes with a warning such-and-such may cause cancer. I do pay attention but find myself unable to avoid exposure to everything that might be bad for me. At this point, I think breathing causes cancer. Should I stop breathing?

Breathing asbestos. Im a goner here too. As a former Navy-guy, I worked down in the boiler room. Hot as hell right there among gigantic steam pipes all encased in asbestos. Thankfully, so far, I have nothing other than a persistent cough and no lung cancer.

Worse draw an inside straight. (Also known as a gutshot or belly buster draw, where you have a straight but are missing the card in the middle.) While I dont play poker, getting cancer is a lot like drawing an inside straight. Our genes get messed up. Maybe we got them from a long-dead ancestor. One clicks over and we find ourselves with a losing cancer hand. Im not sure what happened in my case. My tumor was not genetically profiled. I wish it had been so I would better understand my odds at this point. Will I get another shot at a losing hand?

I know this in jest as no one tries or wants to get cancer. But its interesting to think about everything that causes cancer. Sadly, there are dozens of things. Cancer aside, I am indeed fortunate (and thankful) to be here.

Read more:
Seven 'Sure' Ways to Get Cancer - Curetoday.com

Bone Marrow Stem Cells Comments Off on Seven ‘Sure’ Ways to Get Cancer – Curetoday.com | July 8th, 2020

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:86172.

CAS PubMed Article Google Scholar

Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:66376.

CAS PubMed Article Google Scholar

Boland MJ, Hazen JL, Nazor KL, Rodriguez AR, Gifford W, Martin G, et al. Adult mice generated from induced pluripotent stem cells. Nature. 2009;461:914.

CAS PubMed Article Google Scholar

Kang L, Wang J, Zhang Y, Kou Z, Gao S. iPS cells can support full-term development of tetraploid blastocyst-complemented embryos. Cell Stem Cell. 2009;5:1358.

CAS PubMed Article Google Scholar

Zhao XY, Li W, Lv Z, Liu L, Tong M, Hai T, et al. iPS cells produce viable mice through tetraploid complementation. Nature. 2009;461:8690.

CAS PubMed Article Google Scholar

Shi Y, Inoue H, Wu JC, Yamanaka S. Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov. 2017;16:11530.

CAS PubMed Article Google Scholar

Hasegawa K, Pomeroy JE, Pera MF. Current technology for the derivation of pluripotent stem cell lines from human embryos. Cell Stem Cell. 2010;6:52131.

CAS PubMed Article Google Scholar

Taylor CJ, Bolton EM, Bradley JA. Immunological considerations for embryonic and induced pluripotent stem cell banking. Philos Trans R Soc Lond Ser B Biol Sci. 2011;366:231222.

CAS Article Google Scholar

Devolder K. To be, or not to be? Are induced pluripotent stem cells potential babies, and does it matter? EMBO Rep. 2009;10:12857.

CAS PubMed PubMed Central Article Google Scholar

Fadel HE. Developments in stem cell research and therapeutic cloning: Islamic ethical positions, a review. Bioethics. 2012;26:12835.

PubMed Article Google Scholar

Abad M, Mosteiro L, Pantoja C, Canamero M, Rayon T, Ors I, et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature. 2013;502:3405.

CAS PubMed Article Google Scholar

Knoepfler PS. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells. 2009;27:10506.

CAS PubMed PubMed Central Article Google Scholar

Hentze H, Soong PL, Wang ST, Phillips BW, Putti TC, Dunn NR. Teratoma formation by human embryonic stem cells: evaluation of essential parameters for future safety studies. Stem Cell Res. 2009;2:198210.

PubMed Article Google Scholar

Tan Y, Ooi S, Wang L. Immunogenicity and tumorigenicity of pluripotent stem cells and their derivatives: genetic and epigenetic perspectives. Curr Stem Cell Res Ther. 2014;9:6372.

CAS PubMed PubMed Central Article Google Scholar

Simonson OE, Domogatskaya A, Volchkov P, Rodin S. The safety of human pluripotent stem cells in clinical treatment. Ann Med. 2015;47:37080.

PubMed Article Google Scholar

Ayala FJ. Cloning humans? Biological, ethical, and social considerations. Proc Natl Acad Sci U S A. 2015;112:887986.

CAS PubMed PubMed Central Article Google Scholar

Taylor CJ, Peacock S, Chaudhry AN, Bradley JA, Bolton EM. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell. 2012;11:14752.

CAS PubMed Article Google Scholar

Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011;8:40912.

CAS PubMed Article Google Scholar

Lowry WE, Richter L, Yachechko R, Pyle AD, Tchieu J, Sridharan R, et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A. 2008;105:28838.

CAS PubMed PubMed Central Article Google Scholar

Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:191720.

CAS PubMed Article Google Scholar

Sayed N, Liu C, Wu JC. Translation of human-induced pluripotent stem cells: from clinical trial in a dish to precision medicine. J Am Coll Cardiol. 2016;67:216176.

PubMed PubMed Central Article Google Scholar

Yamanaka S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell. 2012;10:67884.

CAS PubMed Article Google Scholar

Trounson A, DeWitt ND. Pluripotent stem cells progressing to the clinic. Nat Rev Mol Cell Biol. 2016;17:194200.

CAS PubMed Article Google Scholar

Eguchi T, Kuboki T. Cellular reprogramming using defined factors and microRNAs. Stem Cells Int. 2016. https://doi.org/10.1155/2016/7530942.

Article CAS Google Scholar

Moradi S, Asgari S, Baharvand H. Concise review: harmonies played by microRNAs in cell fate reprogramming. Stem Cells. 2014;32:315.

CAS PubMed Article Google Scholar

Ichida JK, Blanchard J, Lam K, Son EY, Chung JE, Egli D, et al. A small-molecule inhibitor of TGF- signaling replaces Sox2 in reprogramming by inducing Nanog. Cell Stem Cell. 2009;5:491503.

CAS PubMed PubMed Central Article Google Scholar

Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol. 2008;26:7957.

CAS PubMed PubMed Central Article Google Scholar

Li Y, Zhang Q, Yin X, Yang W, Du Y, Hou P, et al. Generation of iPSCs from mouse fibroblasts with a single gene, Oct4, and small molecules. Cell Res. 2011;21:196204.

CAS PubMed Article Google Scholar

Hou P, Li Y, Zhang X, Liu C, Guan J, Li H, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science. 2013;341:6514.

CAS PubMed Article Google Scholar

Moradi S, Sharifi-Zarchi A, Ahmadi A, Mollamohammadi S, Stubenvoll A, Gunther S, et al. Small RNA sequencing reveals Dlk1-Dio3 locus-embedded MicroRNAs as major drivers of ground-state pluripotency. Stem Cell Rep. 2017;9:208196.

CAS Article Google Scholar

Greve TS, Judson RL, Blelloch R. MicroRNA control of mouse and human pluripotent stem cell behavior. Ann Rev Cell Dev Biol. 2013;29:21339.

CAS Article Google Scholar

Moradi S, Braun T, Baharvand H. miR-302b-3p promotes self-renewal properties in leukemia inhibitory factor-withdrawn embryonic stem cells. Cell J. 2018;20:6172.

PubMed Google Scholar

Lee YJ, Ramakrishna S, Chauhan H, Park WS, Hong S-H, Kim K-S. Dissecting microRNA-mediated regulation of stemness, reprogramming, and pluripotency. Cell Regen. 2016;5:2.

Article CAS Google Scholar

Hassani SN, Moradi S, Taleahmad S, Braun T, Baharvand H. Transition of inner cell mass to embryonic stem cells: mechanisms, facts, and hypotheses. Cell Mol Life Sci. 2019;76:87392.

CAS PubMed Article Google Scholar

Zhu S, Li W, Zhou H, Wei W, Ambasudhan R, Lin T, et al. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Ctem Cell. 2010;7:6515.

CAS Article Google Scholar

Esteban MA, Wang T, Qin B, Yang J, Qin D, Cai J, et al. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Ctem Cell. 2010;6:719.

CAS Article Google Scholar

Xie M, Tang S, Li K, Ding S. Pharmacological reprogramming of somatic cells for regenerative medicine. Acc Chem Res. 2017;50:120211.

CAS PubMed Article Google Scholar

Ma X, Kong L, Zhu S. Reprogramming cell fates by small molecules. Protein Cell. 2017;8:32848.

CAS PubMed PubMed Central Article Google Scholar

Yoshioka N, Gros E, Li HR, Kumar S, Deacon DC, Maron C, et al. Efficient generation of human iPSCs by a synthetic self-replicative RNA. Cell Stem Cell. 2013;13:24654.

CAS PubMed Article Google Scholar

Yakubov E, Rechavi G, Rozenblatt S, Givol D. Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. Biochem Biophys Res Commun. 2010;394:18993.

CAS PubMed Article PubMed Central Google Scholar

Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med. 2013;19:9981004.

CAS PubMed PubMed Central Article Google Scholar

Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature. 2011;471:637.

CAS PubMed PubMed Central Article Google Scholar

Mayshar Y, Ben-David U, Lavon N, Biancotti JC, Yakir B, Clark AT, et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell. 2010;7:52131.

CAS PubMed Article PubMed Central Google Scholar

Tompkins JD, Hall C, Chen VC, Li AX, Wu X, Hsu D, et al. Epigenetic stability, adaptability, and reversibility in human embryonic stem cells. Proc Natl Acad Sci U S A. 2012;109:125449.

CAS PubMed PubMed Central Article Google Scholar

Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, et al. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 2011;29:113244.

CAS PubMed Article PubMed Central Google Scholar

Liang G, Zhang Y. Genetic and epigenetic variations in iPSCs: potential causes and implications for application. Cell Stem Cell. 2013;13:14959.

CAS PubMed PubMed Central Article Google Scholar

Steyer B, Bu Q, Cory E, Jiang K, Duong S, Sinha D, et al. Scarless genome editing of human pluripotent stem cells via transient puromycin selection. Stem Cell Rep. 2018;10:64254.

CAS Article Google Scholar

Giacalone JC, Sharma TP, Burnight ER, Fingert JF, Mullins RF, Stone EM, et al. CRISPR-Cas9-based genome editing of human induced pluripotent stem cells. Curr Protoc Stem Cell Biol. 2018;44:5B7.

PubMed PubMed Central Google Scholar

Zhang XH, Tee LY, Wang XG, Huang QS, Yang SH. Off-target effects in CRISPR/Cas9-mediated genome engineering. Mol Ther Nucleic Acids. 2015;4:e264.

CAS PubMed PubMed Central Article Google Scholar

Guidance for human somatic cell therapy and gene therapy. Hum Gene Ther. 2001;12:30314.

Daley GQ, Hyun I, Apperley JF, Barker RA, Benvenisty N, Bredenoord AL, et al. Setting global standards for stem cell research and clinical translation: the 2016 ISSCR guidelines. Stem Cell Rep. 2016;6:78797.

Original post:
Research and therapy with induced pluripotent stem cells ...

IPS Cell Therapy Comments Off on Research and therapy with induced pluripotent stem cells … | July 8th, 2020

After case studies of COVID-19, researchers from the Max Planck Institute of Experimental Medicine in Gttingen, Germany, believe that erythropoietin (EPO) could be used to treat COVID-19 patients. A go-to for many dopers in endurance sports, EPO stimulates the production of red blood cells, which can help with oxygen supply in a users brain and muscles. The team of Mac Planck researchers are planning a clinical trial to take a more in-depth look at EPO and its effects on the coronavirus, and they have outlined their reasoning in an articleon the institutes website.

The German team of researchers cite a COVID-19 case from Iran which occurred in March. The patient was infected with the coronavirus, but doctors noted that they also had poor blood values. To combat this, the patient was prescribed EPO in addition to the regular care for COVID-19. Just a week after starting the EPO treatment, the patient was well enough to return home.

RELATED: Ottawa Marathon third-place finisher provisionally suspended for EPO

Researchers also point to South American populations that live at high altitudes, where severe illnesses are rarer than in lower regions. The Mac Planck Institute team writes that this may be because people living at higher altitudes form more EPO and are better adapted to oxygen deficiency because they have more red blood cells.

According to the article, experiments on animals have shown that EPO affectsparts of the brain stem and spinal cord that control breathing. As a result, the researchers write, breathing improves when there is an oxygen deficiency. EPO also has an anti-inflammatory effect on immune cells and could thus attenuate the frequently exaggerated immune response in COVID-19 patients.

RELATED: WADA to fund anti-doping project piloting artificial intelligence

Dr. Hannelore Ehrenreich, one of the researchers on the German team, notes the importance of determining whether EPO could be an effective treatment for the coronavirus.

Because COVID-19 can have such severe health-related consequences, we must investigate any evidence of a protective effect of EPO, Ehrenreich says. After all, there is currently neither a vaccine nor a medication for the disease. We are therefore preparing a proof-of-concept study to investigate the effect of EPO on COVID-19 in humans. The clinical trial will see severely ill COVID-19 patients receiving EPO to see if it can alleviate severe disease progression.

RELATED: More than half of Bahrains athletics medals are tainted by doping scandals

Following the release of the Max Planck article, running coach Steve Magness tweeted, Just waiting for some athlete or coach trying to get a TUE for taking EPO for a mild COVID case. TUE stands for Therapeutic Use Exemption, which allows athletes to use banned substances for legitimate medical reasons. Magnesss tweet had the feel of a joke, but theres a ring of truth to it. Dopers will do a lot to get away with cheating, and if using EPO to treat COVID-19 becomes a widespread treatment, some athletes might actually take advantage of it.

Read this article:
Could EPO be used to treat COVID-19? - Canadian Running Magazine

Spinal Cord Stem Cells Comments Off on Could EPO be used to treat COVID-19? – Canadian Running Magazine | July 8th, 2020

As reported in an eye-opening new research paper, scientists have created tiny human livers out of human skin cells before successfully transplanting them into rats.

What we are planning to do is to start making mini human organs that are universal, explained the papers co-author, Alejandro Soto-Gutirrez, from the University of Pittsburgh.That would change the paradigm of transplants.

The science-fiction-like procedure was done by taking adult skin cells and genetically altering certain genes and transcription factors to create what are known as pluripotent stem cells.

It starts with human skin cells called fibroblasts, in 2006 the pioneering field of genetic-editing led scientists to discover that they can simply take any cell from a living adult and turn it into a pluripotent stem cell.

Pluri, meaning plurality, indicates its ability to carry the genetic code of all organ types, which is how they can become liver cells.

RELATED: For the First Time in the US, Surgeons Pump New Life into Dead Donor Heart for Life-Saving Transplant

According to the Mayo Clinic, the number of people on current waiting lists for liver transplants far exceeds the number of available liver donors. The cost is just as high: the medical journal Inverse reports the average cost of a transplant, accounting for the entire procedure, is about $812,000.

New technologies always reduce the cost of existing products (remember how expensive flat screen televisions were?) and a new paradigm of made-to-order fabrication of organs would likely fulfill all the demand for transplants while lowering the cost at the same time.

As fascinating as it is a little unsettling, the science took a decade to perfect, but is far still from human trials. The tiny organs from human cells continued working normally after they were transplanted into rats bred to have suppressed immune systems otherwise the body would reject the foreign organ.

RELATED: Game-Changing Approval of Liver Transplant Procedure Expected to Halve the Waiting List

The method and associated technology could produce part-time liver grafts, that could prolong the lives of people waiting on the transplant list.

The long-term goal is to create organs that can replace organ donation, but in the near future, I see this as a bridge to transplant, Soto-Gutirrez told Inverse. For instance, in acute liver failure, you might just need a hepatic boost for a while, instead of a whole new liver.

(File photo by OPCW Laboratory in Rijswijk, CC license)

YOUR Friends May Be On The Waiting List For Good NewsShare on Social Media

See the rest here:
Dream of Plentiful Organ Transplants Moves Closer to Reality as Scientists Grow Tiny Working Livers from Skin Cells - Good News Network

Skin Stem Cells Comments Off on Dream of Plentiful Organ Transplants Moves Closer to Reality as Scientists Grow Tiny Working Livers from Skin Cells – Good News Network | July 7th, 2020

Oncology is a branch of study and treatment of cancer. Cancer is disease in which abnormal cells grow and divide without control. Oncology drugs help in diagnosis cancer. Some of the causes of cancer are tobacco and smoking, viral infections, genetic causes, carcinogens, bacterial infections, physical activities, eating habits and age. Various types of cancer that can be treated by oncology drugs are blood cancer, endocrine cancer, lung cancer, bone cancer, skin cancer, genitourinary cancer, gastrointestinal cancer, breast cancer, eye cancer, head and neck cancers and gynaecologic cancer. On the basis of treatment, oncology drugs market can be segmented into chemotherapy, immunotherapy, surgery, radiation therapy, stem cell transplant, hormone therapy and others.

To remain ahead of your competitors, request for a sample [emailprotected] https://www.persistencemarketresearch.com/samples/3312

North America, followed by Europe, has the largest market for oncology drugs due to new drug development, government initiatives and developed healthcare infrastructure in this region. Asia is expected to show high growth rate in the oncology drugs market in next few years due to increasing incidence of cancer cases, rise in the use of tobacco products and growth in aging population in the region.

Technological advancement, increasing incidence of various type of cancers, rise in need for R&D activities in cancer and growing concerns over high death rates due to cancer are driving the market for oncology drugs. In addition, introduction of new drugs and therapies for cancer and government support to improve healthcare condition are expected to drive the market for oncology drugs. However, high cost of cancer treatments, strict government regulations, huge investment involvement in the development and clinical trials of the therapies and side effects of cancer treatments are some of the major factors restraining the growth for global oncology drugs market.

To receive Methodology request here@ https://www.persistencemarketresearch.com/methodology/3312

Growing demographics and economies in the developing countries such as China and India are expected to offer good opportunities in oncology drugs market in Asia. In addition, new innovations in cancer drugs and therapies and rise in awareness about the new drugs and therapies available in the market are expected to offer new opportunities for global oncology drugs market. Personalized medicines, increasing number of mergers and acquisitions, new product launches and rise in number of collaborations and partnerships are some of the trends that have been observed in global oncology drugs market.

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/toc/3312

Some of the major companies operating in the global oncology drugs market are

Originally posted here:
Growing Demand for Oncology Drugs Market to Significantly Increase Revenues Through 2020 - Jewish Life News

Skin Stem Cells Comments Off on Growing Demand for Oncology Drugs Market to Significantly Increase Revenues Through 2020 – Jewish Life News | July 7th, 2020

A man undergoes a rapid HIV test. (CLAUDIO REYES/AFP via Getty)

In a major leap forward in the search for a HIV/AIDS cure, a person has been cured of HIV using a cocktail of medicines in what activists have dubbed a breakthrough as exciting as it was unexpected.

HIV, known as human immunodeficiency virus, hobbles peoples immune systems leaving them more vulnerable to once everyday diseases.

In a new study, presented Tuesday (July 7) at the International AIDS conference 2020, a patient on a relatively simple antiretroviral drugregimen was given a medicine commonly used to treat skin cancer.

Previous milestones of individuals HIV appearing to go into long-term remission resulted from bone-marrow transplants given to infected patients. Similarly, the transplants were intended to treat cancer in the patients, not HIV.

But bone-marrow transplants on top of being costly are unlikely to be realistic or reliable treatment options and are, at times, riddled with risk. Yet, this case involved no invasive medical procedures.

As a result, experts told PinkNews, while they are wearily calling it a cure for the virus, it is difficult how to define the word when instances of the virus demise are so few.

Moreover, they said, caution must be exercised in pivoting the case as a success, as scientists must assess whether the outcome can be replicated.

And while the HIV epidemic continues, advocates have warned that the emergence of the coronavirus pandemic its continually sweeping infection rates and how it is vacuuming the attention of scientists and healthcare officials will no doubt knock back success made in recent years.

Dr Andrea Savarino, of the Instituto Superiore di Sanit in Rome, Italy, explained to HIV advocacy group aidsmap during a video call seen by PinkNews that the patient, one of five, was given an experimental drug commonly used as a skin cancer preventative called Nicotinamide as part of the study.

The medicine boosts the immune system, and some academics have demonstrated how Nicotinamide inhibits advanced stages of HIVinfection in cell culture and works on multiple mechanisms to reel back HIV, Savarino said.

By the end of the study, Savarino said, a common indicator of the virus presence viral DNA was undetectable in the patient. Savarino admitted this was not an optimal marker, but it may give an indication of the size of the viral reservoir.

Researchers have long struggled to find a way to destroy HIV reservoirs clusters of infected immune cells that are not producing new HIV but this strategy, Savarino explained, may provide a possible blueprint.

Even after the patient was taken off of his antiretrovirals treatments, the virus did not rebound, the viral DNA was maintained negative, he said. The antibody response decreased over time, if the antibody decreases, it is possible that the virus has stopped its repetition.

The other four patients did rebound, the researcher said.

He stressed that the antibodies made to fight HIV have not disappeared altogether, but did decrease hes still being monitored in order to understand whether the antibodies might disappear as in the case of Mr Timothy Brown,Savarino added.

Brown, often referred to as the Berlin patient, beat HIV with a combination of stem cell transplants and radiotherapy following a diagnosis of leukaemia.

During the trial, only mild side-effects were observed from the cocktail of medicines: No real side-effects were observed from Nicotinamide, which was in-line with previous trials of the medicines impact on cancer.

However, the HIV expert stressed that those living with HIV should not take Nicotinamide in a non-medical setting, being that it is a potent and still experimental medicine.

I really hope that [the study] boosts further research into a HIV cure because it is the first time such a condition is seen, to my knowledge, in a patient under chronic HIV infection, and without having been subjected to a life-threatening medical procedure such as bone marrow transplant, he said.

However, this is our very first experiment, and I wouldnt foresee beyond that.

This was an unexpected result its proof of a concept that we werent really looking out for, Matthew Hodson, executive director of aidsmap, told PinkNews.

We have had effective treatment for HIV for 34 years but 690,000 people died of AIDS last year.

We anticipate that due to COVIDs disruption of health services there will be an even greater number of AIDS-related deaths this year. People around the world are desperately in need of a cure and this case does give us renewed hope.

Although the news is exciting, at this point we have to proceed with caution. We know that a very small number of people can achieve what appears to be remission with antiretroviral drugs alone and it remains possible that this is the case here.

We need to know whether this finding will be replicated in other people, especially as it was not replicated in four other people on the trial.

This particular treatment is relatively inexpensive and, unlike the bone marrow transplant that resulted in previous cure cases, is not especially dangerous to the patient.

This gives me hope that it could be rolled out widely if we found it to work in other people.

Only one person in the small group given this treatment seems to be cured.

Further trials are necessary to find out whether it works for others and which part of the treatment made the difference. This means that it will be some years yet before this treatment will be accessible.

The global fight against AIDS was staggering even before the COVID-19 pandemic, activists admitted, as the United Nations said Sunday that global HIV targets will not be reached.

The organisations AIDS agency said in a report that COVID-19 may hurl progress against the virus back by a decade or even more.

Data from 2019 shows that more than 38 million people worldwide have acquired HIV a million more than in 2018.

UN officials noted that while some 25.7 million people living with HIV were on antiretroviral treatment in 2019 a feat unimaginable a decade prior it still leaves12.6 million not on the life-saving medications.

Visit link:
History made as first person ever is 'cured' of HIV using medication alone - PinkNews

Skin Stem Cells Comments Off on History made as first person ever is ‘cured’ of HIV using medication alone – PinkNews | July 7th, 2020

Cosmetic Skin CareMarketBusiness Insights and Updates:

The latest Marketreport by a Data Bridge Market Researchwith the title[Global Cosmetic Skin CareMarket Industry Trends and Forecast to 2026].The new report on the worldwide Cosmetic Skin CareMarketis committed to fulfilling the necessities of the clients by giving them thorough insights into the Market. The various providers involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers.The reports provide Insightful information to the clients enhancing their basic leadership capacity identified.Exclusive information offered in this report is collected by analysis and trade consultants.

Global cosmetic skin care market is set to witness a substantial CAGR of 5.5% in the forecast period of 2019- 2026.

Cosmetic skin care is a variety of products which are used to improve the skins appearance and alleviate skin conditions. It consists different products such as anti- aging cosmetic products, sensitive skin care products, anti- scar solution products, warts removal products, infant skin care products and other. They contain various ingredients which are beneficial for the skin such as phytochemicals, vitamins, essential oils, and other. Their main function is to make the skin healthy and repair the skin damages.Get PDF Samplecopy(including TOC, Tables, and Figures) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cosmetic-skin-care-market

Thestudy considers the Cosmetic Skin CareMarketvalue and volume generated from the sales of the following segments:Major Marketmanufacturerscovered in the Cosmetic Skin CareMarketare:LOral, Unilever, New Avon Company, Este Lauder Companies, Espa, Kao Corporation, Johnson & Johnson Services, Inc., Procter & Gamble, Beiersdorf, THE BODY SHOP INTERNATIONAL LIMITED, Shiseido Co.,Ltd., Coty Inc., Bo International, A One Cosmetics Products, Lancme, Clinique Laboratories, llc., Galderma Laboratories, L.P., AVON Beauty Products India Pvt Ltd, Nutriglow Cosmetics Pvt. Ltd, Shree Cosmetics Ltd

By Product

By Application

By Gender

By Distribution Channel

Get Table of Contents with Charts, Figures & Tables @https://www.databridgemarketresearch.com/toc/?dbmr=global-cosmetic-skin-care-market

Based on regions, the Cosmetic Skin CareMarketis classified into North America, Europe, Asia- Pacific, Middle East & Africa, and Latin AmericaMiddle East and Africa (GCC Countries and Egypt)North America (United States, Mexico, and Canada)South America(Brazil, Argentina etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Market Drivers:

Market Restraints:

Key Developments in the Market:

Key Benefits for Cosmetic Skin CareMarket:

Enquire Here For Discount Or Cosmetic Skin CareMarket Report Customization@https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cosmetic-skin-care-market

About Us:Data Bridge Marketresearch endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process Data Bridge set forth itself as an unconventional and neoteric Marketresearch and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best Marketopportunities and foster efficient information for your business to thrive in the Market.We ponder into the heterogeneous Markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the Markettrends. Data Bridge delves into the Markets across Asia, North America, South America, Africa to name few.

Contact Us:Data Bridge MarketResearchUS: +1-888-387-2818UK: +44 208 089 1725Hong Kong: +852 819+2 7475Email: [emailprotected]

Read the original here:
Global Cosmetic Skin Care Market Updates, Future Growth, Business Prospects, Forthcoming Developments by Forecast to 2026 - 3rd Watch News

Skin Stem Cells Comments Off on Global Cosmetic Skin Care Market Updates, Future Growth, Business Prospects, Forthcoming Developments by Forecast to 2026 – 3rd Watch News | July 7th, 2020